Dr. Reddy's Q4FY26 Revenues at ₹7,516 Cr, PAT at ₹220 Cr
Dr. Reddy's reported Q4FY26 revenues of ₹7,516 crore, a 12% YoY increase, with PAT at ₹220 crore. FY26 revenues stood at ₹33,593 crore, up 3% YoY. The company launched generic semaglutide in Canada and India, and acquired Progynova® brands in India. It also received a Gold Medal from EcoVadis.
The announcement details strong financial performance, strategic business developments including new product launches and acquisitions, and positive market reception, all of which have a significant impact on the company's outlook and investor perception.
The company reported strong year-on-year growth in revenues and PAT for Q4FY26 and FY26. Significant business achievements like new product launches and market approvals, along with ESG recognitions, contribute to a positive sentiment.
Dr. Reddy's Laboratories Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenues of ₹7,516 crore for Q4FY26, marking a 12% year-on-year and 14% quarter-on-quarter increase. EBITDA stood at ₹981 crore with a 13% margin, and Profit After Tax (PAT) was ₹220 crore.
For the full financial year FY26, reported revenues reached ₹33,593 crore, a 3% year-on-year growth. EBITDA was ₹7,659 crore (23% margin), and PAT was ₹4,285 crore (13% growth year-on-year).
Key business highlights for Q4FY26 include being the first company to secure approval for generic semaglutide injection for Type 2 Diabetes in Canada, and a Day 1 launch of the same under the brand name ‘Obeda®’ in India. The company also secured approval for generic semaglutide tablets in India and had its BLA for abatacept biosimilar accepted for review by the USFDA. Dr. Reddy's also entered the Hormone Replacement Therapy market with the acquisition of Progynova® and Cyclo-Progynova® in India.
In terms of ESG, the company received a Gold Medal from EcoVadis for FY26, achieving its highest-ever score of 80 and ranking in the top 5% globally. It was also recognized among India’s Top 5 Most Sustainable Companies by BusinessWorld and maintained 'Leadership category' in the Indian Corporate Governance Scorecard for the third consecutive year.
The company's revenue breakdown shows Global Generics contributing ₹6,580 crore (up 13% YoY) and PSAI ₹912 crore (up 5% YoY) in Q4FY26. North America saw significant growth of 51% YoY to ₹1,756 crore, while Emerging Markets grew 29% YoY to ₹1,806 crore. India reported 20% YoY growth to ₹1,566 crore, and Europe grew 14% YoY to ₹1,452 crore.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.